Last 12 months
Inside the activity.
0 purchase rows · 112 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 10 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 16 |
| Jun 2026 | 0 | 15 |
| Jul 2026 | 0 | 12 |
| Aug 2026 | 0 | 15 |
| Sep 2026 | 0 | 23 |
| Oct 2026 | 0 | 7 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2026 Filed May 16, 2026 00:17 UTC |
Goncalves JoanaChief Medical Officer
|
SaleCommon Stock | 100 | $63.52 | $6,352.00 |
DisclosureSEC source: 0000907654-26-000039 · form4.xml · nonDerivative · entry 5 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,377 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. Read SEC document |
| May 15, 2026 Filed May 16, 2026 00:17 UTC |
Goncalves JoanaChief Medical Officer
|
SaleCommon Stock | 2,100 | $62.42 | $131,088.30 |
DisclosureSEC source: 0000907654-26-000039 · form4.xml · nonDerivative · entry 4 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,477 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.02 to $62.89, inclusive. Read SEC document |
| May 15, 2026 Filed May 16, 2026 00:17 UTC |
Goncalves JoanaChief Medical Officer
|
SaleCommon Stock | 4,800 | $61.56 | $295,494.72 |
DisclosureSEC source: 0000907654-26-000039 · form4.xml · nonDerivative · entry 3 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,577 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.93 to $61.90, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| May 15, 2026 Filed May 16, 2026 00:17 UTC |
Goncalves JoanaChief Medical Officer
|
Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0000907654-26-000039 · form4.xml · nonDerivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 16, 2026 00:17 UTC |
Goncalves JoanaChief Medical Officer
|
Exercise / conversionCommon Stock | 3,500 | $6.84 | $23,940.00 |
DisclosureSEC source: 0000907654-26-000039 · form4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2026 Filed May 1, 2026 22:25 UTC |
Sandler Laura LeeChief Operating Officer
|
Exercise / conversionEmployee Warrant (right to buy) · Derivative | 5,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000037 · form4.xml · derivative · entry 8 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,996 Underlying: Common Stock · 5,000 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025. Read SEC document |
| May 01, 2026 Filed May 1, 2026 22:25 UTC |
Sandler Laura LeeChief Operating Officer
|
SaleCommon Stock | 100 | $68.48 | $6,848.00 |
DisclosureSEC source: 0000907654-26-000037 · form4.xml · nonDerivative · entry 7 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 236,984 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. Read SEC document |
| May 01, 2026 Filed May 1, 2026 22:25 UTC |
Sandler Laura LeeChief Operating Officer
|
SaleCommon Stock | 200 | $67.16 | $13,431.00 |
DisclosureSEC source: 0000907654-26-000037 · form4.xml · nonDerivative · entry 6 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 237,084 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.11 to $67.20, inclusive. Read SEC document |
| May 01, 2026 Filed May 1, 2026 22:25 UTC |
Sandler Laura LeeChief Operating Officer
|
SaleCommon Stock | 400 | $66.06 | $26,422.00 |
DisclosureSEC source: 0000907654-26-000037 · form4.xml · nonDerivative · entry 5 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 237,284 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.85 to $66.23, inclusive. Read SEC document |
| May 01, 2026 Filed May 1, 2026 22:25 UTC |
Sandler Laura LeeChief Operating Officer
|
SaleCommon Stock | 300 | $65.10 | $19,530.00 |
DisclosureSEC source: 0000907654-26-000037 · form4.xml · nonDerivative · entry 4 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 237,684 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.85 to $65.28, inclusive. Read SEC document |
| May 01, 2026 Filed May 1, 2026 22:25 UTC |
Sandler Laura LeeChief Operating Officer
|
SaleCommon Stock | 1,800 | $64.15 | $115,467.84 |
DisclosureSEC source: 0000907654-26-000037 · form4.xml · nonDerivative · entry 3 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 237,984 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.59 to $64.55, inclusive. Read SEC document |
| May 01, 2026 Filed May 1, 2026 22:25 UTC |
Sandler Laura LeeChief Operating Officer
|
SaleCommon Stock | 2,200 | $62.58 | $137,685.46 |
DisclosureSEC source: 0000907654-26-000037 · form4.xml · nonDerivative · entry 2 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 239,784 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.33 to $62.83, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4. Read SEC document |
| May 01, 2026 Filed May 1, 2026 22:25 UTC |
Sandler Laura LeeChief Operating Officer
|
Exercise / conversionCommon Stock | 5,000 | $7.80 | $39,000.00 |
DisclosureSEC source: 0000907654-26-000037 · form4.xml · nonDerivative · entry 1 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 241,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2026 Filed Apr 15, 2026 22:45 UTC |
Goncalves JoanaChief Medical Officer
|
Exercise / conversionEmployee Warrant (right to buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000035 · form4.xml · derivative · entry 7 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,492 Underlying: Common Stock · 3,500 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| April 15, 2026 Filed Apr 15, 2026 22:45 UTC |
Goncalves JoanaChief Medical Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0000907654-26-000035 · form4.xml · derivative · entry 6 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,063 Underlying: Common Stock · 3,500 shares Expires 2034-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| April 15, 2026 Filed Apr 15, 2026 22:45 UTC |
Goncalves JoanaChief Medical Officer
|
SaleCommon Stock | 500 | $67.38 | $33,692.00 |
DisclosureSEC source: 0000907654-26-000035 · form4.xml · nonDerivative · entry 5 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,377 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.35 to $67.41, inclusive. Read SEC document |
| April 15, 2026 Filed Apr 15, 2026 22:45 UTC |
Goncalves JoanaChief Medical Officer
|
SaleCommon Stock | 2,273 | $66.56 | $151,300.65 |
DisclosureSEC source: 0000907654-26-000035 · form4.xml · nonDerivative · entry 4 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,877 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.31 to $67.15, inclusive. Read SEC document |
| April 15, 2026 Filed Apr 15, 2026 22:45 UTC |
Goncalves JoanaChief Medical Officer
|
SaleCommon Stock | 4,227 | $65.73 | $277,836.91 |
DisclosureSEC source: 0000907654-26-000035 · form4.xml · nonDerivative · entry 3 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,150 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.31 to $66.29, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| April 15, 2026 Filed Apr 15, 2026 22:45 UTC |
Goncalves JoanaChief Medical Officer
|
Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0000907654-26-000035 · form4.xml · nonDerivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2026 Filed Apr 15, 2026 22:45 UTC |
Goncalves JoanaChief Medical Officer
|
Exercise / conversionCommon Stock | 3,500 | $6.84 | $23,940.00 |
DisclosureSEC source: 0000907654-26-000035 · form4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:09 UTC |
Agarwal ArjunSenior Vice President, Finance
|
SaleCommon Stock | 395 | $41.30 | $16,313.50 |
DisclosureSEC source: 0000907654-26-000032 · form4.xml · nonDerivative · entry 1 Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,863 F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:10 UTC |
Klein Lawrence OttoDirector · Chief Executive Officer
|
SaleCommon Stock | 1,729 | $41.30 | $71,407.70 |
DisclosureSEC source: 0000907654-26-000033 · form4.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 927,309 F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:08 UTC |
Sandler Laura LeeChief Operating Officer
|
SaleCommon Stock | 600 | $41.30 | $24,780.00 |
DisclosureSEC source: 0000907654-26-000031 · form4.xml · nonDerivative · entry 1 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,984 F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:06 UTC |
Goncalves JoanaChief Medical Officer
|
Exercise / conversionEmployee Warrant (right to buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000030 · form4.xml · derivative · entry 8 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,992 Underlying: Common Stock · 3,500 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:06 UTC |
Goncalves JoanaChief Medical Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0000907654-26-000030 · form4.xml · derivative · entry 7 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 214,563 Underlying: Common Stock · 3,500 shares Expires 2034-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:06 UTC |
Goncalves JoanaChief Medical Officer
|
SaleCommon Stock | 641 | $41.30 | $26,473.30 |
DisclosureSEC source: 0000907654-26-000030 · form4.xml · nonDerivative · entry 6 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,377 F5 · kind: These sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:06 UTC |
Goncalves JoanaChief Medical Officer
|
SaleCommon Stock | 1,177 | $41.94 | $49,358.79 |
DisclosureSEC source: 0000907654-26-000030 · form4.xml · nonDerivative · entry 5 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,018 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.75 to $42.28, inclusive. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:06 UTC |
Goncalves JoanaChief Medical Officer
|
SaleCommon Stock | 2,902 | $41.20 | $119,568.78 |
DisclosureSEC source: 0000907654-26-000030 · form4.xml · nonDerivative · entry 4 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,195 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.72 to $41.70, inclusive. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:06 UTC |
Goncalves JoanaChief Medical Officer
|
SaleCommon Stock | 2,921 | $40.11 | $117,158.68 |
DisclosureSEC source: 0000907654-26-000030 · form4.xml · nonDerivative · entry 3 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,097 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $40.64, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:06 UTC |
Goncalves JoanaChief Medical Officer
|
Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0000907654-26-000030 · form4.xml · nonDerivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:06 UTC |
Goncalves JoanaChief Medical Officer
|
Exercise / conversionCommon Stock | 3,500 | $6.84 | $23,940.00 |
DisclosureSEC source: 0000907654-26-000030 · form4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:04 UTC |
Quinlan Paul TGeneral Counsel
|
SaleCommon Stock | 733 | $41.30 | $30,272.90 |
DisclosureSEC source: 0000907654-26-000029 · form4.xml · nonDerivative · entry 1 Quinlan Paul T · CIK 0001333277 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,767 F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 23:47 UTC |
Sandler Laura LeeChief Operating Officer
|
Exercise / conversionEmployee Warrant (right to buy) · Derivative | 5,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000022 · form4.xml · derivative · entry 4 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,996 Underlying: Common Stock · 5,000 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 23:47 UTC |
Sandler Laura LeeChief Operating Officer
|
SaleCommon Stock | 2,675 | $33.81 | $90,435.60 |
DisclosureSEC source: 0000907654-26-000022 · form4.xml · nonDerivative · entry 3 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 237,584 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.66 to $34.33, inclusive. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 23:47 UTC |
Sandler Laura LeeChief Operating Officer
|
SaleCommon Stock | 2,325 | $33.28 | $77,386.00 |
DisclosureSEC source: 0000907654-26-000022 · form4.xml · nonDerivative · entry 2 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 240,259 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.66 to $33.64, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 23:47 UTC |
Sandler Laura LeeChief Operating Officer
|
Exercise / conversionCommon Stock | 5,000 | $7.80 | $39,000.00 |
DisclosureSEC source: 0000907654-26-000022 · form4.xml · nonDerivative · entry 1 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 242,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 17, 2026 22:24 UTC |
Goncalves JoanaChief Medical Officer
|
Exercise / conversionEmployee Warrant (right to buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0000907654-26-000020 · form4.xml · derivative · entry 6 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,492 Underlying: Common Stock · 3,500 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| February 17, 2026 Filed Feb 17, 2026 22:24 UTC |
Goncalves JoanaChief Medical Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0000907654-26-000020 · form4.xml · derivative · entry 5 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 218,063 Underlying: Common Stock · 3,500 shares Expires 2034-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. Read SEC document |
| February 17, 2026 Filed Feb 17, 2026 22:24 UTC |
Goncalves JoanaChief Medical Officer
|
SaleCommon Stock | 936 | $32.78 | $30,686.01 |
DisclosureSEC source: 0000907654-26-000020 · form4.xml · nonDerivative · entry 4 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,018 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.69 to $32.93, inclusive. Read SEC document |
| February 17, 2026 Filed Feb 17, 2026 22:24 UTC |
Goncalves JoanaChief Medical Officer
|
SaleCommon Stock | 6,064 | $32.30 | $195,872.66 |
DisclosureSEC source: 0000907654-26-000020 · form4.xml · nonDerivative · entry 3 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,954 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.68 to $32.67, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| February 17, 2026 Filed Feb 17, 2026 22:24 UTC |
Goncalves JoanaChief Medical Officer
|
Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0000907654-26-000020 · form4.xml · nonDerivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 17, 2026 22:24 UTC |
Goncalves JoanaChief Medical Officer
|
Exercise / conversionCommon Stock | 3,500 | $6.84 | $23,940.00 |
DisclosureSEC source: 0000907654-26-000020 · form4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 22:40 UTC |
Goncalves JoanaChief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $34.39 | $0.00 |
DisclosureSEC source: 0000907654-26-000018 · form4.xml · derivative · entry 2 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2036-01-22 F2 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2026. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 22:40 UTC |
Goncalves JoanaChief Medical Officer
|
GrantCommon Stock | 32,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000907654-26-000018 · form4.xml · nonDerivative · entry 1 Goncalves Joana · CIK 0001756991 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,018 F1 · shares: The grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day). Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 22:40 UTC |
Agarwal ArjunSVP, Finance
|
GrantEmployee Stock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $34.39 | $0.00 |
DisclosureSEC source: 0000907654-26-000016 · form4.xml · derivative · entry 2 Agarwal Arjun · CIK 0002033974 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-01-22 F3 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2026. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 22:40 UTC |
Agarwal ArjunSVP, Finance
|
GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000907654-26-000016 · form4.xml · nonDerivative · entry 1 Agarwal Arjun · CIK 0002033974 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,258 F1 · shares: The grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day). F2 · balance_after: Includes 1,758 shares acquired under the Oruka stock purchase plan on December 8, 2025. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 22:40 UTC |
Sandler Laura LeeChief Operating Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $34.39 | $0.00 |
DisclosureSEC source: 0000907654-26-000017 · form4.xml · derivative · entry 2 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2036-01-22 F2 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2026. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 22:40 UTC |
Sandler Laura LeeChief Operating Officer
|
GrantCommon Stock | 32,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000907654-26-000017 · form4.xml · nonDerivative · entry 1 Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,584 F1 · shares: The grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day). Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 22:38 UTC |
Klein Lawrence OttoDirector · Chief Executive Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 306,700 | $0.00 Strike: $34.39 | $0.00 |
DisclosureSEC source: 0000907654-26-000015 · form4.xml · derivative · entry 2 Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 306,700 Underlying: Common Stock · 306,700 shares Expires 2036-01-22 F2 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2026. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 22:38 UTC |
Klein Lawrence OttoDirector · Chief Executive Officer
|
GrantCommon Stock | 76,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000907654-26-000015 · form4.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 929,038 F1 · shares: The grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.